Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT)

Summary

Heparin-induced thrombocytopenia (HIT) is an adverse complication of heparin caused by HIT antibodies (abs) that recognise platelet factor 4-heparin (PF4/hep) complexes. Several laboratory tests are available for the confirmation and/or refutation of HIT. A reliable and rapid singlesample test is still pending. It was the objective of this study to evaluate a new lateral-flow immunoassay based on nanoparticle technology. A cohort of 452 surgical and medical patients suspected of having HIT was evaluated. All samples were tested in two IgG-specific ELISAs, in a particle gel immunoassay (PaGIA) and in a newly developed lateral-flow immunoassay (LFI-HIT) as well as in a functional test (HIPA). Clinical pre-test probability was determined using 4T's score. Platelet-activating antibodies were present in 34/452 patients, all of whom had intermediate to high clinical probability. PF4/hep abs were detected in 79, 87, 86, and 63 sera using the four different immunoassays. The negative predictive values (NPV) were 100% for both ELISA tests and LFI-HIT but only 99.2% for PaGIA. There were less false positives (n=29) in the LFI-HIT compared to any other test. Additionally, significantly less time was required to perform LFI-HIT than to perform the other immunoassays. In conclusion, a newly developed lateral-flow assay, LFI-HIT, was capable of identifying all HIT patients in a cohort in a short period of time. Beside an NPV of 100%, the rate of false-positive signals is significantly lower with LFI-HIT than with other immunoassay(s). These performance characteristics suggest a high potency in reducing the risk and costs in patients suspected of having HIT.

Keywords

HIT - heparin - diagnostic procedure - immunoassay

• References

• 1 Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl. 01) (Suppl) 9-12.
• 2 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96.
• 3 Hassell K. Heparin-induced thrombocytopenia: diagnosis and management. Thromb Res 2008; 123 (Suppl. 01) (Suppl) S16-21.
• 4 Greinacher A, Alban S, Omer-Adam MA. et al. Heparin induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008; 122: 211-220.
• 5 Greinacher A. Heparin-induced thrombocytopenia: frequency and pathogenesis. Pathophysiol Haemost Thromb 2006; 35: 37-45.
• 6 Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis andmanagement. Br J Haematol 2003; 121: 535-555.
• 7 Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006; 118: 165-176.
• 8 Lo GK, Juhl D, Warkentin TE. et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-765.
• 9 Lubenow N, Eichler P, Albrecht D. et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. Thromb Res 2000; 100: 115-125.
• 10 Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35: 1165-1176.
• 11 Crowther MA, Cook DJ, Albert M. et al. The 4Ts scoring system for heparin-induced thrombocytopenia inmedical-surgical intensive care unit patients. J Crit Care 2010; 25: 287-293.
• 12 Warkentin TE, Sheppard I J, Moore JC. et al. Quantitative interpretation of optical densitymeasurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 1304-1312.
• 13 Bakchoul T, Giptner A, Najaoui A. et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 1260-1265.
• 14 Pouplard C, Leroux D, Regina S. et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010; 103: 145-150.
• 15 Bakchoul T, Giptner A, Bein G. et al. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 2011; 127: 345-348.
• 16 Junqueira DR, Viana TG, Carvalho MD. et al. Accuracy of a prediction model for heparin-induced thrombocytopenia (HIT): An analysis based on individual patient data. Chim Acta 2011. epub ahead of print
• 17 Berry C, Tcherniantchouk O, Ley EJ. et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg 2011. epub ahead of print
• 18 Cuker A, Crowther A. Clinical practice guideline on the evaluation and management of heparin-induced thrombocytopenia. American Society of Hematology 2009; 1-8.
• 19 Warkentin TE, Sheppard I J, Raschke R. et al. Performance characteristics of a rapid assay for anti-PF4/heparin antibodies: the particle immunofiltration assay. J Thromb Haemost 2007; 5: 2308-2310.
• 20 Greinacher A, Michels I, Kiefel V. et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-736.
• 21 Lubenow N, Warkentin TE, Greinacher A. et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006; 117: 507-515.
• 22 Greinacher A, Juhl D, Strobel U. et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5: 1666-1673.
• 23 Warkentin TE, Sheppard JA, Moore JC. et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005; 146: 341-346.
• 24 Schenk S, El-Banayosy A, Morshuis M. et al. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost 2007; 5: 235-241.
• 25 Newman PM, Chong BH. Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br J Haematol 1999; 107: 303-309.
• 26 Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007; 82: 1037-1043.
• 27 Nanwa N, Mittmann N, Knowles S. et al. The direct medical costs associated with suspected heparin-induced thrombocytopenia. Pharmacoeconomics 2011; 29: 511-520.